Abdurrahman
A 68-year-old man from Turkey with relapsed and refractory multiple myeloma travels to Lu Daopei Hospital in China to access BCMA CAR-T cell therapy. Treatment is ongoing.
Why the Family Contacted CancerFax
Searching for advanced treatment in another country is overwhelming when you are also coping with a serious, progressing illness. The family did not know which hospitals genuinely had experience with cell therapy for myeloma, whether Abdurrahman would even be eligible after a transplant, or how to arrange an evaluation abroad. These are the questions CancerFax helped them work through.
Not every hospital offers CAR-T cell therapy for myeloma. Identifying centres with real experience in this specific area takes specialist knowledge.
Eligibility for CAR-T depends on disease status, organ function, and blood counts. Only the treating team can decide this after full evaluation.
Records, translation, communication with the hospital, visas, and travel all have to be coordinated, often under time pressure.
"We had been through so much already. We just wanted to understand if there was still something more that could be tried."β Abdurrahman's family
How CancerFax Helped
CancerFax worked as the navigator and coordinator for the family. We organised the medical records, helped identify a hospital with experience in cell therapy for hematologic cancers, and managed communication and logistics so that the family could focus on Abdurrahman.
PET/CT reports, blood results, treatment history, and the transplant record were compiled into a structured case file for specialist review.
Lu Daopei Hospital in China was identified as a centre with experience in hematologic cancers and CAR-T cell therapy.
Documents and ongoing communication between the family and the hospital team were translated and managed throughout.
Visa documentation, travel, and accommodation were coordinated for Abdurrahman and his accompanying family member.
Abdurrahman's Treatment Journey
Key steps from diagnosis to accessing advanced treatment. This story will be updated as the journey continues.
Abdurrahman was diagnosed with multiple myeloma and began treatment under a hematology team in Turkey.
Over time he received three lines of treatment and underwent an allogeneic stem cell transplant in an effort to bring the disease under lasting control.
A FDG PET/CT scan in December 2024 showed active extramedullary disease in the right chest, with lesions increasing in size and activity compared with earlier scans. His blood counts were low, and he was receiving supportive medication.
With standard options narrowing, the family reached out to CancerFax. The case was reviewed and BCMA CAR-T cell therapy at a specialist centre in China was identified as a path worth exploring.
Abdurrahman travelled to Lu Daopei Hospital, where the hematology and cell therapy team carried out their own evaluation to assess whether he was suitable for BCMA CAR-T cell therapy.
CAR-T cell therapy generally involves collecting the patient's own immune cells, engineering them to recognise the myeloma, and returning them after a short preparatory treatment. The exact plan for any patient is decided by the treating team based on their condition.
Abdurrahman's treatment is ongoing. A formal assessment of how the disease has responded has not yet been made. This page will be updated only when there is a clear, clinically confirmed update from the treating team.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Abdurrahman Is Today
At the time of writing, Abdurrahman is under the care of the team at Lu Daopei Hospital and is being monitored closely. It is too early to describe a response, and CancerFax does not report outcomes before they are confirmed by the treating doctors.
What this stage of his journey reflects is that, even after years of intensive treatment, the family were able to access an evaluation for an advanced cell therapy that was not readily available to them at home. We will share a further update if and when the treating team provides one and the family is comfortable with it being shared.
β"Reaching this point did not feel possible on our own. Having someone help us organise everything and speak to the hospital made a real difference."ββ Abdurrahman's family
What Other Families Can Learn
Abdurrahman's journey so far offers a few practical takeaways for families facing relapsed or refractory myeloma.
When standard treatments stop working, a specialist review can sometimes reveal newer approaches that were not visible locally.
Advanced therapies like BCMA CAR-T have strict criteria. Understanding them early, and letting the treating centre assess them, avoids false hope and wasted time.
Exploring advanced options while the patient is still well enough to travel and undergo treatment can keep more doors open.
Records, translation, hospital communication, and travel can be overwhelming during illness. Coordinated support removes much of that burden.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.